Bristol-Myers Squibb Guides FY24 Adj. EPS Above Estimates As Q4 Results Top Estimates - Update
(RTTNews) - While reporting financial results for the fourth quarter on Friday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue growth guidance for the full-year 2024.
For fiscal 2024, the company now projects adjusted earnings in a range of $7.10 to $7.40 per share on a worldwide total revenue growth in the low single-digits.
On average, 23 analysts polled by Thomson Reuters expect the company to report earnings of $7.00 per share on revenues growth of 1.9 percent to $45.58 billion for the year. Analysts' estimates typically exclude special items.
For the fourth quarter, the company reported net income attributable to Bristol-Myers Squibb of $1.76 billion or $0.87 per share, lower than $2.02 billion or $0.95 per share in the prior-year quarter. Excluding items, adjusted net earnings per share for the quarter was $1.70, compared to last year's $1.82.
Total revenues for the quarter declined 1 percent to $11.48 billion from $11.41 billion in the same quarter last year.
Analysts expected quarterly earnings of $1.53 per share on revenues of $11.19 billion for the quarter.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
I-Mab Inks Partnership With Bristol Myers Squibb To Evaluate Givastomig In Combination Study
Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation
Perspective Therapeutics Inks Clinical Trial Collaboration Agreement With Bristol Myers
Bristol Myers Squibb To Acquire RayzeBio For $62.50/share In All-cash Deal
Bristol Myers Squibb To Acquire Karuna Therapeutics For $330/share Cash
Avidity Biosciences Inks Global Licensing And Research Collaboration Deal With Bristol Myers Squibb
Bristol-Myers Squibb Boosts FY23 Adj. EPS Outlook As Q3 Adj. EPS Tops Estimates
